### VERIFICATION OF A TRANSLATION

I, the below named translator, hereby declare that:

My name and post office address are as stated below:

That I am knowledgeable in the English language and in the language in which the below identified international application was filed, and that I believe the English translation of the international application No. <u>PCT/JP00/03896</u> is a true and complete translation of the above identified international application as filed.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

	Date
	November 29, 2001
Full name of the translator	Hiromichi KAKEHI
Cignotume of the translator	X Kakehi
Signature of the translator Post Office Address <u>Kitahama T</u>	NK Building 7-1 Dosho-machi
	huo-ku, Osaka-shi, Osaka 541-0045
Japan	

Translation



# PATENT COOPERATION TO ATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

\			000
Applicant's or agent's file reference P00-18	FOR FURTHER ACTION		ionofTransmittalofInternational Preliminary
International application No.	International filing date (day/n	nonth/year)	Priority date (day/month/year)
PCT/JP00/03896	15 June 2000 (15.0	6.00)	15 June 1999 (15.06.99)
International Patent Classification (IPC) or n C12N 15/48, C12Q 1/68, 1/70, C			
Applicant OT:	SUKA PHARMACEUTIC	CAL CO., L	TD.
and is transmitted to the applicant acc.  This REPORT consists of a total of  This report is also accompanished amended and are the bar Rule 70.16 and Section 607 of	ccording to Article 36. 4 sheets, includir nied by ANNEXES, i.e., sheets	ng this cover so	eption, claims and/or drawings which have stifications made before this Authority (see
This report contains indications rela	ating to the following items:	<del></del>	
Basis of the report			
II Priority			
Non actablishment	of opinion with regard to novelty	inventive st	en and industrial applicability
I sale of unity of inv		, mromme se	p and maderial approaching
Lack of unity of inv		to novelty in	ventive step or industrial applicability;
V Keasoned statement citations and explan	ations supporting such statemen	to noverty, in	ventive step of industrial applicationity,
VI Certain documents of	cited		
VII Certain defects in th	e international application		
VIII Certain observations	s on the international application	l.	
Date of submission of the demand	Date of	completion of	f this report
16 November 2000 (16.	.11.00)	03 A	august 2001 (03.08.2001)
Name and mailing address of the IPEA/JP	Author	ized officer	
Facsimile No.	Teleph	one No.	



International application No.

PCT/JP00/03896

1.	Basis	i the report
1.	With	egard to the elements of the international application:*
	$\boxtimes$	the international application as originally filed
		the description:
		pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of
	Ш	the claims:
		pages, as originally filed
		pages, as amended (together with any statement under Article 19
		pages, filed with the demand
		pages, filed with the letter of
		the drawings:
		pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of
		e sequence listing part of the description:
	L	pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of,
2.		egard to the <b>language</b> , all the elements marked above were available or furnished to this Authority in the language in which ernational application was filed, unless otherwise indicated under this item.
	These	elements were available or furnished to this Authority in the following language which is:
		the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
		the language of publication of the international application (under Rule 48.3(b)).
		the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/ or 55.3).
3.		regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international inary examination was carried out on the basis of the sequence listing:
		contained in the international application in written form.
	$\boxtimes$	filed together with the international application in computer readable form.
		furnished subsequently to this Authority in written form.
	$\Box$	furnished subsequently to this Authority in computer readable form.
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
	$\boxtimes$	The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4.	Ш	The amendments have resulted in the cancellation of:
		the description, pages
		the claims, Nos.
		the drawings, sheets/fig
5.		This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
*	Repla in thi	ement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16
	and 7	
**	Any re	placement sheet containing such amendments must be referred to under item 1 and annexed to this report.

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

ternational application No.

PCT/JP 00/03896

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

	·····		
Statement			
Novelty (N)	Claims	1-18	YES
	Claims		NO NO
Inventive step (IS)	Claims		YES
	Claims	1-18	NO NO
Industrial applicability (IA)	Claims	1-18	YES
	Claims		NO

#### 2. Citations and explanations

- Document 1: Journal of Virology, 1999, Vol. 73, No. 5, pp. 3351-3559
- Document 2: Journal of Virology, 1995, Vol. 69, No. 10,
  - pp. 6122-6130
- Document 3: Journal of Virology, 1998, Vol. 72, No. 1, pp. 512-519
- Document 4: Journal of Virology, 1997, Vol. 71, No. 3, pp. 1871-1879
- Document 5: AIDS Res. Hum. Retroviruses, 1993, Vol. 9.
  No. 3, pp. 259-265

The existence of mutations in all of the subtypes of the HIV-1 env gene was known within the art before the priority date of the present application. Documents 1 and 2 disclose subtype-specific mutation in the C2 region of the env gene and Documents 3 and 4 disclose subtype-specific mutation in the C3 region of the env gene.

Document 5 discloses assay of HIV-1 RNA using RT-PCR.

In this connection, determination of the subtypes of HIV-1 was an obvious problem in the art at the priority date of the present application. Therefore, a person skilled in the art could easily conceive of determining subtype by detecting mutations in the C2 region and C3 region of the HIV-1 env gene by using the above method



ternational application No. PCT/JP 00/03896

disclosed in Document 5. Moreover, adoption of nested-PCR was a known technique within the art for raising the sensitivity of detection before the priority date of the present invention, and the adoption of said method was thus an option within the ordinary competence of a person skilled in the art.

Moreover, no surprising effect is claimed for the adoption of the constitution of the inventions set forth in Claims 1-18.

Therefore, the inventions set forth in Claims 1-18 do not involve an inventive step because they could be easily deduced from disclosures in Documents 1-5.